This issue brief, Most Favored Nation vs. Human Sustainability: How Federal Price Controls Fight Biology—and Americans Lose,  examines the potential harms of the federal government’s Most Favored Nation (MFN) drug pricing model. While intended to lower medication costs by capping U.S. prices at the lowest rates paid in other wealthy countries, the brief argues that this approach undermines biological realities, threatens biomedical innovation, and could reduce access to lifesaving therapies—particularly for Medicaid beneficiaries and underserved communities. By prioritizing foreign price benchmarks over patient-centered care and personalized medicine, the MFN model risks worsening health disparities and disrupting the U.S. healthcare ecosystem. The brief urges policymakers to consider alternatives that support affordability without compromising timely access to care, innovation, and equity.

View the issue brief.